Rezultati - Wolfram Jung

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody

    Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody od Frank Hartmann, Christoph Renner, Wolfram Jung, Christina Deisting, Marietta Juwana, B Eichentopf, M Kloft, Michael Pfreundschuh

    Izdano 1997
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Test-enhanced learning of clinical reasoning: a crossover randomised trial

    Test-enhanced learning of clinical reasoning: a crossover randomised trial od Tobias Raupach, Jil Cathérine Andresen, Katharina Meyer, Lisa Strobel, Michael Koziolek, Wolfram Jung, Jamie Brown, Sven Anders

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

    A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia od Walter Fiedler, Rolf M. Mesters, Heike Tinnefeld, Sonja Loges, Peter Staib, Ulrich Dührsen, Michael Flaßhove, Oliver G. Ottmann, Wolfram Jung, Franco Cavalli, R. Kuse, Joerg Thomalla, Hubert Serve, A O’Farrell, Mark Jacobs, Nicoletta Brega, P. Scigalla, Dieter K. Hossfeld, Wolfgang E. Berdel

    Izdano 2003
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

    Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective... od Oliver G. Ottmann, Roman Pfeifer, Jean‐Michel Cayuela, Karsten Spiekermann, Wolfram Jung, Joachim Beck, Emmanuel Raffoux, Pascal Turlure, Chantal Himberlin, Françoise Huguet, Andreas Viardot, Knut Wendelin, Albrecht Reichle, Sébastien Maury, Laurence Sanhès, Françoise Isnard, Jean‐Yves Cahn, Stéphane Leprêtre, Patrice Chevallier, Martine Escoffre‐Barbe, Josep‐María Ribera, Dieter Hoelzer, Nicola Goekbuget, Hervé Dombret, Philippe Rousselot

    Izdano 2018
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

    Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label,... od Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden A. Moccia, Richard Greil, Mark P. Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Hänel, Urban Novak, Julia Meißner, Andreas Zimmermann, Stephan Mathas, Josée M Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Sebastian Scholl, Max S Topp, Wolfram Jung, Vladan Vučinić, Hans-Joachim Beck, Andrea Kerkhoff, Benjamin Unger, Andreas Rank, Roland Schroers, Christian Meyer zum Büschenfelde, Maike de Wit, Karolin Trautmann-Grill, Peter Kamper, Daniel Molin, Stefanie Kreissl, Helen Kaul, Bastian von Tresckow, Sven Borchmann, Karolin Behringer, Michael Fuchs, Andreas Rosenwald, Wolfram Klapper, Hans-Theodor Eich, Christian Baues, Athanasios Zomas, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl

    Izdano 2024
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: